Medulloblastoma (MB) is the most common malignant brain cancer in children. Children diagnosed with the disease undergo intense therapy, including surgery, radiation, and high-dose chemotherapy. Although current treatment regimens have improved 5-year survival rates, almost a third of MB patients still die from their disease, and children who survive suffer long-term side effects that affect their quality of life. Continue reading ““Survivin” as a new target to treat brain cancer”
Institute News